Login to Your Account



FDA not excited about serelaxin efficacy data from single trial

By Mari Serebrov
Washington Editor

Tuesday, March 25, 2014

If the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) follows the lead of FDA reviewers Thursday, it will send Novartis AG’s serelaxin back for more testing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription